In this assay of tamoxifen and four metabolites in human serum, the serum samples are deproteinized with an equal volume of acetonitrile, then injected into a small (0.21 x 2 cm) precolumn packed with 5-sm-diameter octadecylsilane (ODS) particles. The samples are concentrated on-column by equilibrating the column with an equivolume solution of water and acetonitrile containing 3 mmol of acetic acid and 2 mmol of diethylamine per liter. The drugs are then directed into an analytical ODS column (0.21 x 10 cm) by changing the mobile phase followed by column switching. The primary alcohol of tamoxifen ("metabolite Y"), 4-hydroxytamoxifen ("metabolite B"), tamoxifen, N-desdimethyltamoxifen ('metabolite Z"), N-desmethyltamoxifen ("metabolite X"), and 4methoxytamoxifen (internal standard) are eluted in this order at a flow rate of 0.3 mLlmin with a mobile phase of acetonitrue/water (91/9 by vol) at low ionic strength (1 mmol of acetic acid and 0.67 mmol of diethylamine per liter) and detected by post-column fluorescence activation by passage through a capillary quartz tube exposed to ultraviolet light. Analytical recovery was close to 100%. Within-day precision corresponded to a CV of 1-5% at serum concentrations of tamoxifen or metabolites >10 /L; the detection limit of the assay for these compounds was about 1 j.tg/L. This fully automated assay has the advantage of simple sample processing, high sample output, low solvent consumption, high analytical recovery of tamoxifen and four metabolites in serum, and determination of all these compounds plus an internal standard in a single run.
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antiestrogen drug pharmacokinetics mass spectrometry Tamoxifen [trans-1-(4--dimethylaminoethoxyphenyl)-1,2-diphenylbut-1-enel, a nonsteroidal anti-estrogen, has been used extensively in the palliative treatment of breast cancer for more than a decade (1) . The biological activity of this drug has been attributed to both the parent compound and its metabolites. N-Desmethyltamoxifen ("metabolite X") is the major metabolite of tamoxifen in human serum, whereas only trace amounts of 4-hydroxytamoxifen ("metabolite B") have been detected (2,3). However, interest has been focused on the latter compound because of its high potency as an anti-estrogen (4). Other metabolites in humans are trans-1-(4-hydroxyethoxyphenyl)-1,2-diphenylbut-1-ene ("metabolite Y") (5, 6) and N-desdimethyltanioxifen ("metabolite Z") (5) . The structures of these compounds are depicted in Figure 1 . develop routine assays for this drug and its metabolites in human plasma. Several techniques have been published. A procedure based on gas chromatography and mass spectrometryis highly specific, but requires derivatization of sample and involves equipment not generally available (2) . The thin-layer and "high-pressure" liquid-chromatographic (HPLC) methods (7) (8) (9) described allinvolve photochemical conversion of tamoxifen and its metabolites to fluorescent phenanthrene derivatives before chromatography.
An HPLC assay with post-column fluorescence activation, developed by Brown et al. (10) , avoids problems related to the variable photochemical degradation of the phenanthrenes.
The published HPLC methods for tamoxifen in serum do not allow the simultaneous determination of the drug and its major metabolites in serum. Furthermore,most assays require a time-consuming extraction of the compounds into an organic phase, evaporation, and redissolving the samples before injection. Sufficient sample clean-up has also been obtained by passing samples through reversed-phase cartridges (11) . The assays based on precolumn derivatization (8,9) include even furtherprocessing, i.e., constantultraviolet illumination of the extract. The variable recovery obtained can be compensated for by using an internal standard, but trying to select a suitable compound has presented problems (10). Another disadvantage with the established assays is the high consumption of the organic solvent, usually methanol, in the mobile phase, owing to the hydrophobic properties of the analytes and the high flow rates used.
Our efforts to develop an improved assay for tamoxifen Nonstandard abbreviations: HPLC, "high-pressure" liquid chromatography; LC/MS, liquid chromatography/mass spectrometry; ODS, octadecylsilane.
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Identity Abbreviation R1 R2 and its metabolites were motivated by the need to evaluate the biological effects and pharmacokinetics of the newly discovered metabolites in serum relative to the kinetics of the parent drug. Furthermore, new therapeutic regimens combining the use of tamoxifen with other endocrine therapies in breast cancer (12) (13) (14) (15) suggest the possibility of pharmacokinetic interaction.
4-Hydroxytainoxifen
Finally, both tamoxifen and its active metabolites
in serum must be monitored to optimize dose schedules and to evaluate patient compliance.
Here we describe a simple assay for the determination of tamoxifen and four metabolites in human serum. With this assay, which exploits the recent development of "low dispersion" liquid chromatography (16), we obtained on-column concentration and separation of these compounds under conditions characterized by low acetonitrile content and low ionic strength, respectively. The internal standard was synthesized from 4-hydroxytamoxifen by derivatization in the presence of diazomethane (17) . Diazomethane in ether was added to a solution of 4hydroxytamoxifen in methanol (400 mg in 10 mL), then stirred for 30 mm at room temperature. The reaction mixture was analyzed and purified on a 0.46 x 10 cm reversed-phase column packed with 3-pm particles of ODS-Hypersil, eluted isocratically with a mobile phase of acetonitrile/water (84/16 by vol) containing 3 mmol of acetic acid and 2 mmol of diethylamine per liter. Four ultravioletabsorbing peaks, including 4-hydroxytamoxifen, were observed; the peak with longest retention time was analyzed in the chromatographic system routinely used for determination of tanioxifen and its metabolites in serum (see below), and was separated from these compounds. Therefore, the material in this peak was regarded as a suitable internal standard. The selected peaks from repeated runs were pooled, evaporated, and subjected to liquid chromatography/mass spectrometry (LC/MS) with a Model 201 mass spectrometer (Vestec, Houston, TX).The mass of the molecular ion (M + 1Y was 402 mlz. We tentatively identified the compound as methoxytamoxifen.
MaterIals and Methods
Standards. Tamoxifen, metabolite Y, 4-hydroxytamoxifen, N-desdimethyltamoxifen, and N-desmethyltamoxifen were dissolved in 100% methanol at a concentration of 4 g/L.
We diluted these stock solutions to known concentrations, either in acetomtrile/water (1/1 by vol) or in serum.
Procedures
Sample processing. Serum was routinely processed by mixing samples with an equal volume of 100% acetonitrile; we removedthe precipitated protein by centrifugation. The supernates were transferred to sample vials, capped, and analyzed.
Chromatography.
The HPLC system was programmed to inject 250-FL samples into the 0.21 x 2 cm precolumn packed with 5-pm particles of ODS-Hypersil and equilibrated with acetonitrile/water (1/1, by vol) containing 3 mmol of acetic acid and 2 mmol of diethylamine per liter. Under these conditions the analytes are concentrated on the preco- To determine the within-run precision (CV) of the assay, we assayed 10 replicates of serum with added tamoxifen, metabolite Y, 4-hydroxytamoxifen, N-desdimethyltamoxifen, and N-desmethyltanioxifen, each at a concentration of 800, 100, or 10 pgIL. The between-day precision was determined by assaying, on 10 different days, sera from another batch prepared in the same way.
We included the internal standard in all samples by adding this compound to the acetonitrile used for deproteinizing the samples. The amount added was adjusted to give a fluorescence peak corresponding to that produced by about 100 pg of tamoxifen per liter. Assay standard curve and detection limit. We prepared a standard curve by adding known concentrations of tamoxifen and its metabolites, ranging between 1600 and 0.5 pg/L, to serum. The detection limit was determined by extracting serum samples containing added tamoxifen and its metabolites, at concentrations of 20, 10, 4, 2, 1, or 0.5 pgfL.
Instrumentation
We used a Hewlett-Packard liquid chromatograph (Model HP 1090), equipped with a ternary solvent-delivery system, an HPLC autosampler, a column-switching valve, and a 250-pL injection syringe. The columns were mounted in an oven and the temperature was set at 40#{176}C. The effluent from the column was connected to a post-column converter with a 0.17 mm (i.d.) stainless-steel tube. The converter ( Figure 2 ) was built at our laboratory, as follows:
We obtained a flexible capillary quartz tube, 1 m x 0.2 mm (i.d.), by removing the coating from a fused silica tubing. We then connected the silica tubing to a stainlesssteel 0.17 mm (i.d.) tubing by using a zero-dead-volume butt connector (Supelco, Bellefonte, PA). We made every effort to avoid dead volume, which seriously deteriorates the chromatographic resolution of the low-dispersion LC system. We mounted the fused silica tubing in a reflector chamber, To identifSr the eluting peaks, we connected the effluent from the column to a LC/MS thermospray system (Vestec). Before it entered the thermospray probe, the effluent was mixed with 0.1 mmoIIL ammonium acetate reagent, delivered at a rate of 0.7 mL/min via a zero-dead-volume Tconnector.
Results
Extraction procedures. We prepared serum samples to contain 10, 100, or 800 pg each of tamoxifen, metabolite Y, 4-hydroxytamoxifen, N-desdimethyltamoxifen, and N-desmethyltamoxifen per liter. All samples contained the same concentration of internal standard. We obtained complete recovery of these compounds from serum extracted with an equal volume of acetonitrile (Table 1) .
Liquid chromatography. Figure 3 shows chromatograms of serum from a patient not taking tamoxifen (blank serum, trace B); drug-free serum with added tamoxifen, metabolite Y, 4-hydroxytamoxifen, N-desdimethyltamoxifen, and Ndesmethyltamoxifen (20 or 400 pg/L each), and the internal standard (traces A and C); and serum from a patient who had received 40 mg of tamoxifen twice daily for months (trace D).
We phase by more than twofold, tamoxifen and N-desdimethyltamoxifen co-eluted in all elution systems tested, including variations in acetonitrile concentration (60-100%) and pH (obtained by changing the relative amounts of diethylamine and acetic acid).
We also observed that these two compounds co-eluted when the concentration of acetomtrile deviated markedly from 91%.
Metabolite Y eluted close to the solvent front, such that a serum peak caused some interference at low concentrations of this compound (<4 jzg/L). Also, 4-hydroxytamoxifen eluted at a point corresponding to a slight fluctuation in the baseline, which interfered with peak integration at low concentrations.
We therefore used peak height instead of peak area for the determination of this compound in the concentration range 1-3 pg/L. The hydrophobic compounds-tamoxifen, N-desdimethyltamoxifen, N-desmethyltamoxifen, and the internal standard-showed the longest retention times, eluting in a region where the baseline was stable. All compounds, except N-desdimethyltamoxifen, showed about the same fluorescence yield (Figure 3) . Figure 4, trace B, shows a single-ion monitoring trace of the same serum sample shown in Figure 3C . We set the instrument to monitor one ion at a time, at selected times: mlz 362 (metabolite Y) from 0 to 5 mm, miz 388 (4hydroxytamoxifen) from 5 to 7.5 mm, mlz 372 (tamoxifen) from 7.5 to 10 mm, mlz 344 (N-desdimethyltamoxifen) from 10 to 12 min, mlz 358 (N-desmethyltamoxifen) from 12 to 15 mm, and mlz 402 (4-methoxytamoxifen) from 15 to 21 mm. The response differed markedly between the compounds. 4-Hydroxytamoxifen produced a large peak; tainoxifen, metabolite Y, and N-desmethyltamoxifen gave a moderate response; and N-desdimethyltamoxifen gave a small response. The internal standard could not be detected. Inspectionof Figure 3C and D and Figure 4B and C shows that the heights of the separate peaks relative to that of the standards were about the same for both detector systems. This observation confirms the identity of these peaks in chromatograms from the patient treated with tamoxifen. was somewhat higher, about 2 ig/L (Figure 3) . The detection limit of metabolite Y and 4-hydroxytamoxifen was also about 2 pgfL, owing to the chromatographic interference at low concentrations described above.
The within-day precision (CV) of the assay of tamoxifen and its metabolites was about 1% at 800 pgfL, 1% at 100 pgfL,and 3% at 10 p.g/L. The corresponding between-day CVs were about 4%, 3%, and 6%, respectively. Notably, the Fig. 3D . The time-tablefor the selectionof the monitored ions (as described in detail in text) is shown below the time axis, and the abundance of theseparateeons is plottedvs retention time precision was not significantly improved by including the internal standard and correcting the values accordingly. Details of the precision experiments are given in Table 2 .
Interference from various drugs. We tested various drugs for interference with the tamoxifen assay by analyzing serum from patients who were taking therapeutic doses of the following drugs but not tamoxifen: acetaminophen, allopurinol, amitriptyline, chlorpromazine, chiorthalidone, codeine, dexamethasone, diazepam, diflunisal, doxepin, furosemide,flurazepam,glibenclainide, hydrochlorothiazide, ipratropium bromide, isosorbide dinitrate, megestrol acetate, methotrexate, morphine, naproxen, nortriptyline, propranolol, sulfamethoxazole, terbutaline sulfate, theophylline, trimethoprim, and warfarin. None of these drugs caused interference with the assay.
Serum concentration
curves. Figure 6 shows the serum proffles of tamoxifen and N-desmethyltamoxifen aftera single 30-mg dose of tamoxifen. Tamoxifen showed a peak concentration of 70 ugfL in serum 4 h afterintake.The serum concentration of N-desmethyltamoxifen increased rapidly during the first 4 h, then increasedmore slowly. Figure 7 shows the accumulation of tamoxifen and its metabolites in serum during long-term treatment with tamoxifen (30 mg/day). Tamoxifen and N-desmethyltamoxifen progressively increased for several weeks, to about 100 and 200 1zgfL, respectively. N-Desdimethyltamoxifen and 11)01 Our method is based on a simple processing of serum samples. The one-step protein-precipitation procedure with an equal volume of acetonitrile avoids the laborious extraction procedures, evaporation of organic material, and reconstitution of samples often included in published assays (6-9, 11,18) . Simple and reproducible sample processing is impor-Without 1.5.
Whhln-day
With 1.5. Time after drug ingestion (h) Fig. 6 . Concentration curves for tamoxifen and N-desmethyttamoxifen in serumaftera singleingestion of 30 mg of tamoxifen tant for a high sample output, and this, together with automatic injection of a large sample volume, explains the high reproducibility of the method. Notably, the reproducibility of the assay was in fact not increased by including an internal standard (Table 2) , so we did not routinely use one. However, the internal standard may become useful if extraction of serum into an organic solvent is necessary for whatever reasons.
Between
We injected 250 L of sample into a small precolumn having a total volume of 69 tL. The analytes in this sample are retained on the top of the precolumn, which had been equilibrated with an equivolume solution of acetonitrile and water containingacetic acid and diethylamine. This oncolumn concentrationis necessarytoachieve the sensitivity necessary to detect small amounts of tamoxifen and its metabolites in serum, as in single-dose studies. We could further decrease the detection limit by extracting large serum samples into diethyl ether, or by increasing the injection volume, but this was not required in monitoring the drug concentrations in serum after ingestion of therapeutic doses of tamoxifen.
We directed the flow-through to waste and the analytes to the analytical column, using an automated column-switch-ing valve. The column-switching has the following impact on the performance of the present method: (a) There is less interference from fluorescent material eluting in or near the solvent front. (b) The analytical column is by-passed during sample clean-up, and is not exposed to salts from serum. (theseserum constituents cause the chromatographic resolution, which is critically dependent on elution at low ionic strength, to deteriorate. (c) The analytical column is protected from the material present in the large sample of crude serum extract injected into the column, thereby prolonging column life.
The precolumn and the analytical column have the same internal diameter, 2.1 mm, which is less than that of conventional HPLC columns. These small columns are eluted at a low flow rate, i.e., 0.3 mb/mm, in the present assay, which results in low consumption of mobile phase. Because elution of tamoxifen and its metabolites from a reversed-phase column requires a mobile phase containing a high percentage of organic solvent, the low flow rate significantly affects the cost of the assay. In addition, small-bore columns require only low amounts of packing material, for a further cost reduction.
In addition to simple sample processing and high precision, we obtained total recovery of tamoxifen and four serum metabolites. In preliminary experiments about 75%, 68%, and 57% of 4-hydroxytamoxifen, tamoxifen, and N-desmethyltamoxifen were recovered after extraction with diethyl ether (data not shown). Moreover, to our knowledge, this is the only tamoxifen assay that determines the parent drug and four metabolites in human serum plus an internal standard in a single run. We obtained this separation by eluting the analytical column at low ionic strength.
The present assay was useful for studying the pharmacokinetics of tamoxifen and some metabolites in serum after single doses ( Figure 6) , and during various therapeutic regimens including chronic dosing with tamoxifen ( Figure  7) , alone or in combination with other drugs. We developed this assay for serum samples, but have observed that it works equally well with plasma.
One person can prepare several hundred samples within a few hours. Because of low solvent consumption there is no need to replenish the mobile phase, and prolonged unattended analyses are possible. Thus, the number of samples to be analyzed by this procedure is limited only by the capacity of the sample tray.
In conclusion, our low-dispersion liquid-chromatographic assay for tamoxifen and metabolites in serum exploits recent developments in liquid-chromatographic hardware. This assay is characterized by simple sample processing, high recovery of analytes, low consumption of solvent and packing material, high sample output, high precision, and simultaneous quantification of the parent drug and four serum metabolites. In addition, the assay is fullyautomated.
